The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran
{{output}}
Background: This study evaluates the cost-effectiveness of adding ocrelizumab to supportive care for primary progressive multiple sclerosis (PPMS) in Iran. Resear... ...
